Fibulins (FBLNs), a family of extracellular matrix proteins, have recently been shown to act as tumor suppressors or activators in different cancers, and the underlying molecular mechanisms of their action in cancer remain unclear. We have previously shown that the expression of FBLN3 is suppressed by promoter hypermethylation and is associated with invasiveness in aggressive nonsmall cell lung cancer. In this study, we evaluated the roles and signaling mechanism of FBLN3 in lung cancer stem cells (CSCs). Forced expression of FBLN3 suppressed invasion and migration of lung adenocarcinoma cells and decreased the expression of epithelial-to-mesenchymal transition (EMT) activators, including N-cadherin and Snail. Stemness activities of lung adenocarcinoma cells were also suppressed by FBLN3 as indicated by a decrease in spheroid formation and the levels of stemness markers such as Sox2 and b-catenin. These effects of FBLN3 were mediated by the glycogen synthase kinase-3b, GSK3b/b-catenin pathway, and the upstream regulators of GSK3b, including phosphoinositide 3-kinase (PI3K)/AKT and insulin-like growth factor-1 receptor (IGF1R), were inactivated by FBLN3. Moreover, IGF1R was shown to be a direct target of FBLN3, which competitively inhibited insulin-like growth factor (IGF) action. To confirm the effect of FBLN3 on lung CSCs, aldehyde dehydrogenase-positive (ALDH þ ) A549 lung CSCs were sorted and treated with recombinant FBLN3 protein. FBLN3 clearly suppressed EMT, stemness activity and the overactivated IGF1R/PI3K/AKT/GSK3b pathway of the ALDH þ CSC subpopulation. In addition, injection of recombinant FBLN3 protein around subcutaneous xenografts established with ALDH þ CSCs in athymic nude mice significantly suppressed tumor growth and progression. Overall, our results show that FBLN3 suppresses both EMT and self-renewal of the lung CSCs by modulating the IGF1R/ PI3K/AKT/GSK3b pathway and that FBLN3 would be useful as an alternative CSC therapy.
INTRODUCTION
Lung cancer is one of the most common causes of death from cancer worldwide. Non-small cell lung cancer (NSCLC), which accounts for B80% of all lung cancers, is associated with a poor 5-year survival (15%) owing to its aggressiveness. 1 Advances in our understanding of cell signaling pathways, such as the epidermal growth factor receptor (EGFR) pathway, which controls tumor cell survival, have identified genetic and regulatory aberrations related to tumorigenesis, and selection of patients using genetic markers and molecular-targeted therapy has improved clinical outcomes. 2 Growing evidence has suggested that many types of cancers, including lung cancer, may be driven by cancer stem cells (CSCs), which may be responsible for the poor outcome of lung cancer. 3, 4 Therefore, targeting signaling pathways that are critical to lung CSCs has been proposed as another promising strategy for cancer treatment. 5 CSCs are a rare set of undifferentiated cells that can initiate tumor formation and generate multipotent progenitors, producing a heterogeneous population of cancer cells. They are defined as cells that form cell spheres and have tumorigenic ability in in vivo xenograft assays. Experimental evidence supporting the CSC hypothesis was first reported in a study of leukemia-initiating CSCs. 6 CSCs have now been identified in many human cancers, 7, 8 including breast, brain and lung cancers. CSCs have been suggested to be a cause of tumor aggressiveness and poor prognosis because they show intrinsic resistance to radiation and chemotherapy. 3 Moreover, the discovery of a CSC population that undergoes an epithelial-tomesenchymal transition (EMT), a driver of metastasis, has bolstered the importance of CSC research for cancer therapy development. 4 The CSC hypothesis has fundamental clinical implications. Although current treatment strategies may affect the bulk of the tumor cells, they leave behind therapy-resistant CSCs, which serve as a reservoir for disease recurrence and metastasis. 9 Therefore, elucidation of the molecular pathways that regulate the characteristics of CSCs and their interaction with their environment is important for identifying potential therapeutic targets.
The fibulins (FBLNs) are a family of secreted glycoproteins that are characterized by repeats of epidermal growth factor (EGF)-like domains. 10 They are widely expressed extracellular matrix (ECM) proteins and participate in cell-to-matrix communication and stabilization of the ECM structure, functions that are important for normal organogenesis and embryonic development. FBLNs are also associated with the development of solid tumors such as breast and colorectal cancers, 11 but their role in cancer initiation and progression has been difficult to define. FBLNs are expressed in tumors and inhibit or promote cell growth, according to the cellular contexts. Recent studies have shown that FBLN5 overexpression is involved in tumorigenicity of colon cancer 11 and the suppression of tumor growth and invasive behavior in lung cancer. 12 The role of FBLN3, a homolog of FBLN5, in tumorigenicity also differs in various cell lines, 13, 14 and its functions in cancer remain unknown.
We showed that FBLN3 suppresses the invasive behavior of A549 NSCLC cells through transcriptional inhibition of matrix metalloproteinase (MMP)-7 and MMP-2. 15 Invasiveness is a typical characteristic of EMT and CSCs. Moreover, A549 cells are known to include a stem-like cell population that comprises B24% of the total cell population. 16 On the basis of these data, we investigated whether FBLN3 can regulate lung CSCs. The EMT and stemness of FBLN3-overexpressing A549 cells were analyzed, and the effects of FBLN3 protein on lung CSCs sorted from a population of A549 NSCLC cells were also analyzed.
RESULTS

FBLN3 inhibits EMT in lung adenocarcinoma cells
We showed previously that overexpression of FBLN3, the expression of which is diminished in the human lung adenocarcinoma tissue (Supplementary Figure 1) , decreased the invasiveness of A549 cells by suppressing MMP expression. 15 Forced expression of FBLN3 in A549 NSCLC cells also significantly decreased cell migration and altered cell morphology, from spindle-shaped to cobblestone-like cells (Figure 1a , left panel). By contrast, suppression of FBLN3 expression in H460 cells increased cell invasion/migration and induced morphological changes to spindle-shaped cells (Figure 1a , right panel). Such morphological changes and increased cell migration/invasiveness are typical characteristics of EMT. Expression of FBLN3 in NSCLC cells changed mesenchymal cell-like characteristics to epithelial cell-like characteristics. On the basis of these findings, we hypothesized that FBLN3 is a negative regulator of EMT in NSCLC cells.
EMT is a process by which the primarily E-cadherin-dependent cell contacts between contiguous epithelial cells break down. 17 During EMT, E-cadherin is downregulated and N-cadherin is upregulated by the transcription factors Twist and Snail, respectively. 18, 19 Expression of ZEB1, which represses E-cadherin gene expression, is also elevated. 20 The intermediate filament protein vimentin, a requisite regulator of mesenchymal cell migration, is another important marker of EMT, which regulates EMT induction via Slug and oncogenic H-Ras. 21 A549 cells expressed very low levels of E-cadherin, but N-cadherin and vimentin were present at significantly high levels (Figure 1b) . Transcription factors related to EMT, including Twist, Snail and ZEB1 were also detectable. Slug expression was very low in A549 cells; although, it is known to be a typical EMT regulator in lung cancer. 21 These mesenchymal phenotypes of A549 cells converted to those of epithelial cells by overexpressing FBLN3. FBLN3 also negatively regulates stemness of lung adenocarcinoma cells The importance of EMT as a driver of invasion and metastasis is being increasingly recognized. Recent evidence has highlighted a link between EMT and the CSCs that initiate and maintain tumors. 22 Therefore, we characterized stemness-associated properties of mesenchymal A549 cells and examined the effect of FBLN3 on these properties.
CSCs can be cultured in suspension in serum-free medium containing growth factors to generate floating spheroid bodies. 23 The sphere-forming assay is widely used to identify stem cells retrospectively based on the utility of the assay in evaluating selfrenewal and differentiation at the single-cell level in vitro. 24 In A549 cell cultures, spheroid formation was seen within 10 days (Figure 2a ), indicating that A549 cells possesses a significant portion of cancer stem-like cells. In these cells, stemness markers such as b-catenin, Notch2 and stemness-related transcription factors (Sox2 and Oct3/4) 25 were expressed in significant amounts (Figure 2b ). However, FBLN3 overexpression in A549 cells inhibited spheroid formation (Figure 2a ) and suppressed the expression of stemness markers (Figure 2b ), implying that FBLN3 suppressed the self-renewal activity of the CSC subpopulation in A549 cells. FBLN3 overexpression also inhibited cell growth of A549 cells (Figure 2c ) as shown by the colony-forming assay. The growth of other lung cancer cell lines was similarly inhibited by exogenous FBLN3 supplied by FBLN3-enriched conditioned media ( Supplementary   Figures 2a and b) . Treatment with FBLN3-enriched conditioned media also decreased the expression of stemness and EMT markers in lung cancer cells (Figure 2d) , and the blockade of these responses by the FBLN3 antibody (Supplementary Figure 2c) confirmed that extracellular FBLN3 is a negative regulator of stemness and EMT in NSCLC cells.
FBLN3 treatment decreased b-catenin through the IGF1R/PI3K/ AKT/GSK3b pathway Recent reports have described the crosstalk between signaling pathways related to EMT and stemness. 4, 25 The Smad complex is suggested to be a point of signal convergence associated with the Wnt pathway 26 and EMT, 27 and b-catenin is one of the important components in the Smad complex. Although the signaling pathway invoked by FBLN3 has not been identified in lung cancer, the results described in the previous section suggested that FBLN3 overexpression inhibited the phosphorylation-mediated activation of AKT, extracellular signal-related kinase and nuclear factor-kB, as we have shown previously. 15 Suppression of AKT activity by FBLN3, which consequently inhibits tumor cell migration and invasion, was also shown in nasopharyngeal carcinoma. 28 AKT phosphorylates a number of molecules, including glycogen synthase kinase-3b (GSK3b), an upstream regulator of b-catenin. Phosphorylation of GSK3b by AKT inactivates GSK3b and, consequently, stabilization of b-catenin. 30 As shown in Figure 4a , small interfering RNA-mediated downregulation of AKT expression in A549 cells decreased the phosphorylation of AKT and GSK3b, resulting in degradation of b-catenin. Snail protein, the stability of which is regulated by GSK3b, 31 was also decreased, and these results were consistent with the phenotypes of FBLN3-overexpressing A549 cells. In NSCLC cells, significant expression of b-catenin and Snail was detectable, and this expression was changed by overexpression and/or suppression of FBLN3 ( Figure 4b ). The levels of phospho-GSK3b in these cells were affected by FBLN3, implying that the regulation of b-catenin and Snail in lung cancer cells by FBLN3 is mediated via GSK3b phosphorylation. Phosphorylation of AKT and phosphoinositide 3-kinase (PI3K), an upstream regulator of AKT, was also affected by FBLN3 expression.
Insulin and insulin-like growth factor (IGF)-1 are known to stimulate the b-catenin pathway through activation of the IGF1R/PI3K/AKT pathway and phosphorylation of GSK3b in hepatocarcinogenesis. 30 In addition, insulin-like growth factor-1 receptor (IGF1R) expression is associated with poor survival in surgically treated NSCLC patients, 32 making it an attractive therapeutic target in lung cancer. Considering these lines of evidence, we supposed that IGF1R was a major stimulator of PI3K/AKT/ GSK3b signaling in NSCLC cells that, in turn, results in GSK3b phosphorylation and b-catenin stabilization. We examined the effect of FBLN3 on the IGF1R signaling pathway. Forced expression of FBLN3 reduced phosphorylation-mediated activation of IGF1R. By contrast, FBLN3 knockdown increased IGF1R phosphorylation (Figure 4b ). In addition, treatment with an IGF1R inhibitor, AG1024, which mimics the inhibitory effect of FBLN3, clearly decreased phospho-GSK3b and depleted b-catenin and Snail (Figure 4c ). These data confirmed that there is crosstalk between the IGF1R/ PI3K/AKT/GSK3b signaling pathway and signaling pathways related to EMT and stemness in A549 lung cancer cells and that FBLN3 negatively regulates the IGF1R signaling pathway. Phosphorylation of EGFR, another upstream regulator of the PI3K/AKT pathway in lung cancer cells, was also affected by FBLN3 (Figure 4b ) and AG1024 (Figure 4c) .
To examine the function of extracellular FBLN3 protein more precisely, we prepared recombinant FBLN3 protein and analyzed its effects and interactions with cellular components. Recombinant FBLN3 with a hexa-histidine (HIS) tag at the C-terminus (FBLN3-HIS), expressed in Chinese hamster ovary (CHO)-K1 cells, was purified using nickel beads (Figure 5a ). Exogenous treatment with recombinant FBLN3 inhibited EMT or stemness of A549 cells. Levels of b-catenin, Sox2 and Oct3/4 were decreased (Figure 5b ), confirming the activity of recombinant FBLN3. Decreased invasion/migration and spheroid formation as well as immunohistochemical analysis of EMT markers by treatment with recombinant FBLN3 also showed (Supplementary Figure 3) that FBLN3 is a negative regulator of EMT and stemness in A549 cells.
To capture FBLN3-targeting molecules, pull-down and coimmunoprecipitation assays were performed using FBLN3-HIS and A549 cell total lysates and analyzed by western blotting using antibodies against IGF1R and EGFR, which are speculated to be receptors for FBLN3. As shown in Figure 5c , both IGF1R and EGFR were confirmed in the FBLN3 complexes captured by the nickel beads. In addition, FBLN3 was also identified in the immunoprecipitated complex using IGF1R and EGFR antibodies. These interactions were also confirmed in H460 cells, which express endogenous FBLN3, and in FBLN3-overexpressing A549 cells (Supplementary Figure 4) . Moreover, FBLN3 competitively inhibited the interaction of IGF-1 or EGF with their specific receptors, consequently suppressing receptor phosphorylation (Figure 5d) . Inhibition of IGF1R activation by FBLN3 also led to decreased AKT phosphorylation. EGFR activation was also inhibited by FBLN3; phospho-AKT induced by EGF was diminished by treatment of the cells with recombinant FBLN3, but only to a small extent, confirming that the EGFR pathway is not the main signaling pathway for activation of PI3K/AKT in A549 cells. 33 Overall, these findings suggest that negative regulation of EMT in lung cancer cells by FBLN3 is mediated by its effects on the PI3K/AKT/GSK3b pathway. Furthermore, the results showed that the upstream regulators of the PI3K/AKT/GSK3b pathway, IGF1R and EGFR, are direct targets of FBLN3.
FBLN3 suppresses self-renewal and EMT-associated properties of ALDH þ cancer stem-like cells and reduces the growth of xenografted tumors In NSCLC, chemo-and radiation-therapy fail to eliminate all the tumor cells due to cellular resistance and metastasis. 34 Recent studies have indicated that EMT and the tumorigenic CSC subpopulation have important roles in cancer metastasis, drug resistance and poor prognosis of NSCLC. 35 Our results showed that EMT and stemness of lung cancer cells could be regulated by FBLN3 treatment, implying that FBLN3 may be useful in eliminating lung CSCs.
To determine the effect of FBLN3 on lung CSCs more clearly, a cancer stem-like population isolated from A549 cells was treated with FBLN3 protein exogenously. Aldehyde dehydrogenase (ALDH) activity has been proposed to be a useful marker for CSCs, which exhibit elevated ALDH1 expression. 36 Cells that have high ALDH activity can be sorted and isolated from a mixed population of cells using the ALDEFLUOR assay followed by fluorescence-activated cell sorting. 37 In NSCLCs, cancer cells with strong ALDH1A1 activity exhibit CSC features and elevated CD133 expression. 38 In our study, ALDH þ and ALDH À A549 cells were sorted using the ALDEFLUOR assay (Figure 6a) . To evaluate the tumor-restoration capability of the sorted cells, ALDH þ or ALDH À subpopulations were injected into athymic nude mice. Injection of ALDH þ cells (5 Â 10 5 ) resulted in visible tumors 18 days after injection ( Figure 6b) ; however, injection of ALDH À cells (up to 1 Â 10 7 ) did not induce tumor formation 30 days after inoculation. ALDH þ subpopulations were more resistant to g-radiation compared with those derived from the unsorted cells (Figure 6c ). In ALDH þ cells, transcript levels of ALDH1A1 and ALDH1A3, and protein levels of EMT-stemness markers, including b-catenin and Snail, were higher compared with those in ALDH À cells (Figures 6d, e) . CD133, CD40 and CD90 stem cell markers, which have been recently highlighted, were also elevated in ALDH þ subpopultions compared with ALDH À subpopulations (Supplementary Figure 5) . In ALDH þ cells, phosphorylated (p)-IGF1R, p-AKT and p-GSK3b were also upregulated. Most importantly, FBLN3 expression was undetectable in ALDH þ cells but detectable in ALDH À cells.
When these stem-like ALDH þ populations were treated with exogenous FBLN3 protein, cell invasion and migration were severely diminished (Figure 7a ). The ability of the ALDH þ lineage to form spheroid bodies was also significantly decreased by FBLN3 (Figure 7b ), and cell growth was decreased also (Figure 7c) . Treatment of ALDH þ cells with FBLN3 strongly diminished stemness and EMT markers, including Sox2, Snail and b-catenin ( Figure 7d ). The levels of p-IGF1Rb and p-GSK3b in ALDH þ populations were also diminished by treatment with FBLN3. Molecular events similar to those induced by FBLN3 in ALDH þ populations also occurred upon treatment with an IGF1R inhibitor, AG1024, further confirming that exogenous FBLN3 inhibits the activation of IGF1R (Figure 7e ). When ALDH þ cells were treated with FBLN3-enriched conditioned media, the expression of MMP-2 and MMP-7 was decreased ( Figure 7f ) as shown in our previous study using unsorted A549 cells. 15 Invasiveness and migration ability were decreased, and p-AKT, p-GSK3b (Supplementary Figure 6 ) and b-catenin (Figure 7f ) in ALDH þ populations were also decreased by treatment with FBLN3-enriched conditioned media. However, these effects of FBLN3 were blocked by the addition of an FBLN3 antibody into the conditioned media, confirming the specific actions of FBLN3 on ALDH þ cells.
Finally, we examined the effect of FBLN3 on lung CSCs using subcutaneous xenografts of ALDH þ cells in athymic nude mice. When ALDH þ cells were injected subcutaneously, the tumor burden was measurable by B18 days after inoculation (Figure 6b ). Nude mice injected with ALDH þ cells were divided into two groups (n ¼ 5 per group): a group in which FBLN3-HIS was injected peritumorally at 18, 21 and 24 days after tumor injection; and the control group in which vehicle (phosphate-buffered saline) was injected. Treatment with FBLN3 severely reduced the growth of the xenografted tumors, compared with the tumors in the control group (Figure 7g) . These results suggest that FBLN3 may have therapeutic applications in treatment of lung CSCs.
On the basis of our in vitro and in vivo data, we concluded that suppression of FBLN3 expression is closely associated with the EMT process and cancer cell stemness in NSCLC, and that exogenous treatment with FBLN3 targeting the PI3K/AKT/GSK3b pathway could be an effective lung CSC therapy.
DISCUSSION
Pathways that regulate self-renewal and cell fate in CSC systems are beginning to be elucidated. The reactivation of varied developmental signaling cascades (Wnt/b-catenin, Sonic hedgehog and Notch) combined with augmented DNA repair and ATP-binding cassette transporter-mediated drug efflux in CSCs may be responsible for their resistance to conventional therapies. 39 Furthermore, changes in the local microenvironment of CSCs may also influence their behavior. For example, the highly tumorigenic and metastatic properties of lung CSCs are known to be associated with the efficient production of cytokine-network proteins and with the specific signaling pathways involving stem cell factor and its receptor c-kit (CD117). 40 Thus, molecular targeting of highly tumorigenic and metastatic CSCs must be considered from various aspects to improve the efficacy of current anticancer strategies. Currently, promising therapeutic approaches include targeting of certain signal transduction pathways (for example, RAC, WNT, PI3K and PML) with smallmolecule inhibitors or targeting specific cell-surface molecules (for example, CD44) with effective cytotoxic antibodies. 41 Some of these drugs are at preclinical or early clinical phases of development, and it remains to be seen how many will actually progress to clinical application. 42 FBLNs are extracellular glycoproteins that associate with the ECM, and considerable research has been focused on their structural roles within the ECM. However, recent findings of their involvement in tumor growth and aggressiveness and as a component of the tumor microenvironment have led to closer examination of its actions, and there have been several reports regarding the regulation of cancer cell signaling by FBLNs, such as the Notch signaling pathway in glioma 43 and the EGF-AKT pathway in pancreatic carcinoma cells. In adults, FBLN3 is widely distributed in various tissues, including the lung. Normal lung tissue expresses a significant amount of FBLN3. However, FBLN3 expression is very low in invasive lung adenocarcinoma, 15, 45 a finding that was confirmed by immunohistochemical staining of lung adenocarcinoma tissue (Supplementary Figure 1) . In lung adenocarcinoma, FBLN3 expression is inactivated by promoter methylation. 15 Particularly, lung CSCs sorted based on ALDH activity showed more diminished FBLN3 expression than non-tumorigenic cancer cells with low ALDH activity (Figure 6e ). On the basis of these data, we examined whether FBLN3 is a negative regulator of lung CSCs. Forced expression of FBLN3 or exogenous treatment with FBLN3 in NSCLC stem cells effectively inhibited their stemness-and EMTrelated properties. FBLN3 exerts these effects by inhibiting the PI3K/AKT/GSK3b pathway through IGF1R.
IGF-IR is a multifunctional receptor tyrosine kinase involved in several biological processes, including cell proliferation, differentiation, DNA repair and cell survival. It was implicated in the maintenance of malignant phenotypes, and interruption of IGF-1R signaling inhibited cancer cell growth and motility in in vitro and in vivo models. 46 Therefore, IGF1R has been identified as a potential molecular target for several cancer types, including breast cancer, cervical cancer, malignant melanoma and NSCLC. 47 Moreover, the activation of IGF-1R and its downstream pathways has critical roles in the normal development of many tissues and is believed to be important for the maintenance of tissue-resident adult stem cells. 48 IGF-1R-mediated signaling is also required for embryonic stem cell self-renewal, 49 indicating an important role for IGF-1R in stem cell biology. Therefore, the functions of IGF1R in CSCs have been the focus of recent investigations in several cancers, including breast cancer and hepatocellular carcinoma. 50, 51 In this study, we showed that activation of IGF1R signaling is important for the maintenance of lung CSCs. More importantly, our data support a role for FBLN3 as an inhibitor of IGF1R signaling, and the results of the xenograft model support the potential application of FBLN3 to lung CSC therapy. We expect that supplementation of FBLN3 in lung cancer cells, to levels comparable to those in normal cells, will suppress the growth of lung CSCs.
EGFR, a receptor tyrosine kinase sharing common downstream components with IGF-1R, was also revealed to be a target molecule of FBLN3 in CSCs derived from A549 cells. FBLN3 competed with EGF to bind EGFR and suppressed phosphorylation-mediated activation of EGFR. However, the inhibition of IGF1R by FBLN3 seems to be superior to FBLN3-mediated EGFR inhibition for suppressing stemness of CSCs, considering that the resistance of A549 cells to EGFR inhibitors, such as gefitinib, is caused by heterodimerization of EGFR with IGF1R. 52 Recently, cotargeting EGFR and IGF-IR was proposed to be a more effective cancer therapy, and treatment with an IGF1R antibody in combination with EGFR inhibitors results in synergistic or supraadditive anti-tumor effects in experimental models. 53 Considering these data, FBLN3 is a well-tailored regulator of receptor tyrosine kinase/PI3K/AKT signaling by simultaneous blockade of EGFR and IGF1R signaling in lung CSCs, and treatment of FBLN3 is likely be a very effective strategy to regulate CSCs.
In conclusion, our data showed that FBLN3 is a negative regulator of stemness in lung CSCs that exerts its effects through IGF1R signaling and suggest that FBLN3 may be applicable as an alternative cancer therapy for aggressive lung adenocarcinoma. 15 To confirm the action of FBLN3, the FBLN3 antibody (0.4 mg/ml) was preincubated with conditioned media enriched with FBLN3 and added to AL þ CSCs. (g) Effect of FBLN3 on xenograft tumor growth of AL þ CSCs. Recombinant FBLN3 protein (5 mg/18 g of body weight in mice) was injected into the site of tumor implantation three times after tumor cells were grown (18, 21 and 24 days after tumor implantation) and the tumor volume was measured as described in Methods.
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Human lung carcinoma cell lines and CHO-K1 cells were obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea). A549 cells were transfected with the FBLN3 overexpression vector (pcFBLN3) 15 using Lipofectamine (Invitrogen, Carlsbad, CA, USA). After 72 h, cells were analyzed by reverse transcription-polymerase chain reaction and western blotting. The FBLN3-HIS expression vector was constructed by cloning inserts, amplified from complementary DNA of H460 cells using the following primers: forward, 5 0 -CGGAATTCATGTTGAAAGCCCTTTTCCTAACTATG-3 0 , and reverse, 5
0 -CCGGCTCGAGCTAGTGGTGGTGGTGGTGGTGAAATGAAA ATGG-3 0 , into pcDNA3.1 (Invitrogen). The resultant expression vector (pcFBLN3-HIS) was transfected into CHO-K1 cells, and stable transfectants were selected with 500 mg/ml G418 (Merck, Darmstadt, Germany). Small interfering RNA transfections were performed as described previously 15 using small interfering RNA targeting FBLN3 (Invitrogen), b-catenin (Invitrogen) and AKT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Invasion and migration assays
Cell invasion and migration were performed as described previously 15 using Matrigel-coated invasion/migration chambers (8-mm pores; BD Biosciences, San Jose, CA, USA). The stained cells were counted under a light microscope in four randomly chosen fields, with results expressed as means of triplicates from a representative of two independent experiments.
Western blotting and reverse transcription-PCR analysis
Western blotting was performed as previously described 15 with primary antibodies specific for FBLN3, b-catenin, cyclin D1, Twist, Zeb-1, PI3K p110 (Santa Cruz Biotechnology), E-cadherin, N-cadherin (BD Biosciences), vimentin (Thermo Fisher Scientific, Fremont, CA, USA), Snail, Slug, Notch2 (Abcam, Cambridge, UK), Oct3/4 (Millipore, Billerica, MA, USA), Sox2, Nanog, p-Tyr1068 EGFR, EGFR, p-IGF1Rb (Tyr1131)/insulin receptor b (Tyr1146), IGF1Rb (111A9), p-Ser473 Akt, Akt, p-GSK3b and GSK3b (Cell Signaling Technology, Danvers, MA, USA), and the corresponding secondary antibodies (anti-mouse or anti-rabbit immunoglobulin G horseradish peroxidase-linked antibodies (Cell Signaling Technology)). Reverse transcription-PCR analysis was performed as described previously 15 using primers described in Table 1 .
Sphere formation assay and sphere culture For the sphere formation assay, cells (2 Â 10 4 cells/ml) suspended in 0.4% agarose in stem cell-permissive medium containing Dulbecco's Modified Eagle Medium, DMEM-F12 (Invitrogen), 20 ng/ml EGF, 20 ng/ml basic fibroblast growth factor (bFGF) and B27 Serum-Free Supplement (50 Â ; Invitrogen) were seeded on 60-mm dishes precoated with 0.8% agar in complete growth medium and incubated at 37 1C in a 5% CO 2 humidified incubator. After 10 days, spheres were counted and photographed. For sphere culture, A549 or ALDH þ cells were cultured in stem cell-permissive medium. Spheres were collected after 5-7 days, and resuspended in stem cell-permissive medium with 3 mg/ml FBLN3-HIS protein.
Colony-forming assay
The colony formation assay was performed as previously described. 15 Immunoprecipitation assay of FBLN3-interacting proteins FBLN3-HIS-overexpressing CHO-K1 cells were lysed in NP-40 lysis buffer 15 and the supernatants were collected. One milligram of cell lysate was incubated with 20 ml of Ni-NTA agarose (QIAGEN, Hilden, Germany) overnight at 4 1C, and bead-protein complexes were used for western blot analysis. For precipitating the FBLN3-interacting proteins, cell lysates were incubated with Ni-NTA agarose pre-bound with FBLN3-HIS overnight at 4 1C and resolved on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels after a brief washing step. For the immunoprecipitation, cell lysates were mixed with FBLN3-HIS for 2 h at 4 1C, and then conventional procedures for immunoprecipitation were performed as described previously. 15 Cell lysates containing 10 mg of protein were analyzed in parallel experiments.
Purification of FBLN3-HIS from the conditioned media of FBLN3-HIS-overexpressing CHO-K1 cells
To prepare FBLN3-HIS-enriched conditioned media, FBLN3-HIS-overexpressing CHO-K1 cells (5 Â 10 5 cells) were cultured in CHO-S-SFM II media (Invitrogen). Supernatants were collected and used for purification of FBLN3-HIS using Ni-NTA agarose (Qiagen). Purified FBLN3-HIS was used after confirming purity by SDS-polyacrylamide gel electrophoresis and Western blot analysis.
CSC sorting from the A549 NSCLC cell line using the ALDEFLUOR assay
The ALDEFLUOR assay (STEMCELL technologies, Vancouver, BC, Canada) was performed to isolate and characterize CSC populations in A549 cells according to the manufacturer's instructions. Briefly, 10 6 cells were resuspended in Aldefluor assay buffer containing the ALDH substrate. As a negative control, an aliquot of Aldefluor-exposed cells was immediately quenched with a specific ALDH inhibitor, diethylaminobenzaldehyde. Following a 30-min incubation at 37 1C, the cells were washed and sorted as ALDH þ and ALDH À cells using a FACSAria flow cytometer (BD Biosciences).
Fluorescence microscopy Cells (5 Â 10 4 ) cultured on glass coverslips in six-well plates were fixed with 4% paraformaldehyde and were incubated with the primary antibodies, in phosphate-buffered saline with 1% BSA and 0.1% Triton X-100, at 4 1C overnight. The antibodies used were E-cadherin, N-cadherin (BD Biosciences), vimentin (Thermo Fisher Scientific) and Snail (Abcam). Staining was visualized using an Alexa Flour488-conjugated anti-rabbit antibody (Invitrogen). Nuclei were counterstained using 4, 6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St Louis, MO, USA). Stained cells were visualized with a fluorescence microscope (Olympus IX71; Olympus, Tokyo, Japan).
Xenograft tumor growth assay
Tumorigenicities of ALDH þ , ALDH À or unsorted A549 cells were assayed by subcutaneous inoculations of 5 Â 10 5 cells resuspended in 100 ml of phosphate-buffered saline into the flanks of 5-week-old athymic BALB/c female nude mice (n ¼ 5 per group). Tumor size was measured using calipers (calculated volume ¼ shortest diameter 2 Â longest diameter/2) in each 3-day interval. Five weeks after cell inoculation, the grafts were removed and photographed. To test the antitumor efficacy of FBLN3 on lung cancer stem-like cells, two groups of xenografted tumor mice inoculated with ALDH þ A549 cells were prepared. FBLN3-HIS (5 mg/18 g of body weight) was injected into the tumor inoculation site three times after the tumor burdens were measurable (18, 21 and 24 days after tumor injection). The control group was injected with phosphate-buffered saline. Tumor size was measured in each 3-day interval; 6 weeks after inoculation, the grafts were removed and photographed. All animal studies were approved by the institutional review board (KRIBB Institutional animal care and use committee/KRIBB-IACUC, approval number: KRIBB-AEC-4253), and all procedures were performed in accordance with institutional guidelines for animal care.
Statistical analysis
Statistical analysis was performed using PRISM version 5.0 (GraphPad). Data are presented as the mean ± standard deviation (s.d.). Comparisons between two groups were made using two-tailed unpaired t-test. One-way analysis of variance (ANOVA) was applied to test for multiple comparisons. Statistical significance was assigned to P-values less than 0.05. 
